|Bid||26.05 x 800|
|Ask||0.00 x 1100|
|Day's Range||64.10 - 64.10|
|52 Week Range||58.18 - 93.89|
|Beta (5Y Monthly)||0.91|
|PE Ratio (TTM)||N/A|
|Earnings Date||Apr 26, 2022 - May 02, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||100.33|
ALung Technologies Inc., whose HemoLung product developed out of the University of Pittsburgh helps patients with acute respiratory distress, has been acquired by a London-based medical technology company. LivaNova (NASDAQ: LIVN) acquired ALung for $10 million with additional payments on sales-based milestones in the future, according to LivaNova's first-quarter earnings report that was released Wednesday. "ALung products are complementary to LivaNova's ACS portfolio and, as such, the business and financial results will be included in the company's ACS (Advanced Circulatory Support) segment," LivaNova said.
LivaNova (LIVN) delivered earnings and revenue surprises of -7.69% and 3.09%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
LONDON, May 04, 2022--LivaNova PLC, a market-leading medical technology and innovation company, today reported results for the quarter ended March 31, 2022.